WHO ICTRP trial
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy…
NL-OMON53869 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON53869 |
|---|---|
| Public title | A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) |
| Scientific title | A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) - WU-CART-007 |
| Primary sponsor | Wugen, Inc. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Australia;France;Germany;Netherlands;United Kingdom;United States of America |
| Conditions | Leukemia (TALL) / Lymphoma (LBL);10024324 |
| Interventions | WU-CART-007 is an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor (CAR) targeting human cluster of differentiation (CD) 7. It will be supplied as… |
| Registration date | Dec 21, 2022 |
| Target size | 4 |
| Secondary IDs | 2021-004324-14;2021-004324-14;NL83142.000.22 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: